{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.89","upperLimit":"3.52","value":"2.10"},{"groupId":"OG001","lowerLimit":"0.89","upperLimit":"2.33","value":"1.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve confirmed PR or better. PR: \\>=50% reduction of serum M-protein \\& reduction in 24h urinary M-protein by \\>=90%/\\<200mg/24 h.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"OG001","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only participants who achieved confirmed CR or PR as the best overall response were evaluated.","reportingStatus":"POSTED","timeFrame":"Up to approximately 263 weeks","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}